Priority Review awarded to Xtandi for prostate cancer
admin 22nd August 2019 Uncategorised 0Back in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC.
More: Priority Review awarded to Xtandi for prostate cancer
Source: News